Cognition Therapeutics In... (CGTX)
Cognition Therapeutics Statistics
Share Statistics
Cognition Therapeutics has 61.97M shares outstanding. The number of shares has increased by 54.71% in one year.
| Shares Outstanding | 61.97M |
| Shares Change (YoY) | 54.71% |
| Shares Change (QoQ) | 49.16% |
| Owned by Institutions (%) | 27.37% |
| Shares Floating | 50.22M |
| Failed to Deliver (FTD) Shares | 21.95K |
| FTD / Avg. Volume | 1.37% |
Short Selling Information
The latest short interest is 815.7K, so 1.96% of the outstanding shares have been sold short.
| Short Interest | 815.7K |
| Short % of Shares Out | 1.96% |
| Short % of Float | 2.32% |
| Short Ratio (days to cover) | 1.07 |
Valuation Ratios
The PE ratio is -0.82 and the forward PE ratio is -1.23. Cognition Therapeutics's PEG ratio is 0.
| PE Ratio | -0.82 |
| Forward PE | -1.23 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 1.49 |
| P/FCF Ratio | -0.98 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cognition Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.65, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.65 |
| Quick Ratio | 2.65 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.02 |
| Interest Coverage | 2158.64 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.36M |
| Employee Count | 25 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -78.68% in the last 52 weeks. The beta is 1.03, so Cognition Therapeutics's price volatility has been higher than the market average.
| Beta | 1.03 |
| 52-Week Price Change | -78.68% |
| 50-Day Moving Average | 0.54 |
| 200-Day Moving Average | 0.76 |
| Relative Strength Index (RSI) | 40.3 |
| Average Volume (20 Days) | 1.6M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -53.97M |
| Net Income | -33.97M |
| EBITDA | -53.97M |
| EBIT | -34M |
| Earnings Per Share (EPS) | -0.86 |
Balance Sheet
The company has 25.01M in cash and 535K in debt, giving a net cash position of 24.47M.
| Cash & Cash Equivalents | 25.01M |
| Total Debt | 535K |
| Net Cash | 24.47M |
| Retained Earnings | -175.16M |
| Total Assets | 30.23M |
| Working Capital | 18.41M |
Cash Flow
In the last 12 months, operating cash flow was -28.47M and capital expenditures 0, giving a free cash flow of -28.47M.
| Operating Cash Flow | -28.47M |
| Capital Expenditures | 0 |
| Free Cash Flow | -28.47M |
| FCF Per Share | -0.72 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CGTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CGTX is $6.5, which is 1447.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.5 |
| Price Target Difference | 1447.6% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -9.72 |
| Piotroski F-Score | 2 |